Z Zhao1, Y Xu1, J Lu1, J Xue1, P Liu2. 1. Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, 107 Wenhua Xi Road, Jinan, 250012, Shandong, People's Republic of China. 2. Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, 107 Wenhua Xi Road, Jinan, 250012, Shandong, People's Republic of China. peishuliu@126.com.
Abstract
PURPOSE: HO-1 has been proved to be associated with tumor aggressivity and poor prognosis in various cancers. Our study provides the first study to demonstrate the relationship of HO-1 expression and clinical characteristics in ovarian cancer patients. METHODS: Immunohistochemistry and western blotting were used to examine the expression of HO-1 in tissue species and fresh tissues. CCK-8 was used to investigate cell viability. Transwell chamber was performed to estimate migration and invasion capacities in A2780 and Skov-3 cells. RESULTS: Immunohistochemistry and western blotting showed that the expression of HO-1 was higher in ovarian cancer tissues than normal ovarian tissues. High expression of HO-1 was significantly associated with serous ovarian cancer, high FIGO stage, lymph node metastasis, and non-optimal debulking. Patients with high expression of HO-1 exhibited an unfavorable prognosis. In vitro inducing the expression of HO-1 promoted the proliferation and metastasis of A2780 and Skov-3 cells, with the increased expressions of mesenchymal marker (Vimentin), epithelial-mesenchymal transition-associated transcript factor (Zeb-1), anti-apoptotic protein (Bcl-2), and the decreased expressions of epithelial marker (Keratin) and pro-apoptotic protein (Bax). Meanwhile, after incubating A2780 and Skov-3 together with HO-1 inhibitor, above results could be reversed. CONCLUSION: HO-1 might be a potential marker for prediction of ovarian cancer prognosis and a target for ovarian cancer treatment.
PURPOSE:HO-1 has been proved to be associated with tumor aggressivity and poor prognosis in various cancers. Our study provides the first study to demonstrate the relationship of HO-1 expression and clinical characteristics in ovarian cancerpatients. METHODS: Immunohistochemistry and western blotting were used to examine the expression of HO-1 in tissue species and fresh tissues. CCK-8 was used to investigate cell viability. Transwell chamber was performed to estimate migration and invasion capacities in A2780 and Skov-3 cells. RESULTS: Immunohistochemistry and western blotting showed that the expression of HO-1 was higher in ovarian cancer tissues than normal ovarian tissues. High expression of HO-1 was significantly associated with serous ovarian cancer, high FIGO stage, lymph node metastasis, and non-optimal debulking. Patients with high expression of HO-1 exhibited an unfavorable prognosis. In vitro inducing the expression of HO-1 promoted the proliferation and metastasis of A2780 and Skov-3 cells, with the increased expressions of mesenchymal marker (Vimentin), epithelial-mesenchymal transition-associated transcript factor (Zeb-1), anti-apoptotic protein (Bcl-2), and the decreased expressions of epithelial marker (Keratin) and pro-apoptotic protein (Bax). Meanwhile, after incubating A2780 and Skov-3 together with HO-1 inhibitor, above results could be reversed. CONCLUSION:HO-1 might be a potential marker for prediction of ovarian cancer prognosis and a target for ovarian cancer treatment.
Authors: Norberto A Gandini; María E Fermento; Débora G Salomón; Diego J Obiol; Nancy C Andrés; Jean C Zenklusen; Julián Arevalo; Jorge Blasco; Alejandro López Romero; María M Facchinetti; Alejandro C Curino Journal: Tumour Biol Date: 2014-03
Authors: Matthias Mayerhofer; Stefan Florian; Maria-Theresa Krauth; Karl J Aichberger; Martin Bilban; Rodrig Marculescu; Dieter Printz; Gerhard Fritsch; Oswald Wagner; Edgar Selzer; Wolfgang R Sperr; Peter Valent; Christian Sillaber Journal: Cancer Res Date: 2004-05-01 Impact factor: 12.701
Authors: Barbara Wegiel; David Gallo; Eva Csizmadia; Clair Harris; John Belcher; Gregory M Vercellotti; Nuno Penacho; Pankaj Seth; Vikas Sukhatme; Asif Ahmed; Pier Paolo Pandolfi; Leszek Helczynski; Anders Bjartell; Jenny Liao Persson; Leo E Otterbein Journal: Cancer Res Date: 2013-10-11 Impact factor: 12.701